ANGLE plc Announces Appointments: Interim CEO and Senior Board Advisor

Rhea-AI Summary

ANGLE plc (OTCQX:ANPCY) announced senior leadership changes on 16 October 2025: Peter Collins is appointed interim Chief Executive Officer and Klaas de Boer joins as a senior advisor to the Board. The company will be renamed CelLBxHealth plc.

Collins brings >25 years in oncology diagnostics and drug-development roles, joining in a non‑board capacity. De Boer brings >25 years of venture and finance experience and multiple board roles; the company said his experience will support a restructure and funding planned for Q4 2025. The announcement also lists investor relations contacts and advisors.

Positive

• Interim CEO with >25 years oncology diagnostics leadership
• Senior advisor with >25 years venture and finance experience
• Planned Q4 funding support identified with board-level advisory

Negative

• Interim CEO role is temporary, signalling leadership transition
• Company disclosed a restructure and funding process in Q4 2025, creating near-term execution uncertainty

GUILFORD, SURREY, AL / ACCESS Newswire / October 16, 2025 / ANGLE plc (to be renamed CelLBxHealth plc) (AIM:AGL)(OTCQX:ANPCY), a world-leading circulating tumour cell (CTC) intelligence company with tests for use in research, drug development and clinical oncology, announces that it has strengthened its management team through two senior hires.

Peter Collins has been appointed as interim Chief Executive Officer of the Company and Klaas de Boer joins as a senior advisor to the Board.

Peter Collins brings over 25 years of experience in oncology drug and diagnostics development, having held senior executive positions across both private and publicly listed companies. He joins the Company following a series of successful leadership roles at leading oncology diagnostics organisations, including Chief Executive Officer at SAGA Diagnostics, Chief Business Officer at Inivata, Vice President, Biopharma Business Development at Guardant Health, and Head of Diagnostics at GSK.

Throughout his career, Peter has demonstrated a consistent record of building high-performing teams and driving commercial growth across international healthcare markets. As interim CEO, he joins the Company in a non-board capacity.

Klaas de Boer holds numerous board positions with both public and private international companies including Xeros plc, SmartKem, Inc. and General Fusion, Inc. He began his career with McKinsey & Company before transitioning to venture capital more than 25 years ago; initially with Baan Investment, and later as Managing Partner with Entrepreneurs Fund. His experience in the finance and technology sectors will be invaluable as the Company goes through a restructure and funding in Q4.

Dr Jan Groen, Executive Chairman commented:

"Peter is an exceptional leader with a proven track record of commercial excellence, disciplined execution, and innovation. The Board is delighted that he has agreed to serve as interim CEO while we continue the process to make a permanent appointment. We are also delighted to have Klaas assisting the Board and management team during the coming period."

For further information:

ANGLE plc Dr Jan Groen, Executive Chairman	+44 (0) 1483 343434 investors@angleplc.com
Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper (Corporate Finance) Sunila de Silva (Corporate Broking) Nigel Birks (Life Science Specialist Sales)	+44 (0) 20 7220 0500
FTI Consulting Simon Conway, Ciara Martin, Sam Purewal Matthew Ventimiglia (US)	+44 (0) 203 727 1000 +1 (212) 850 5624

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014).Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc (to be re-named CelLBxHealth plc)

ANGLE plc is a global precision CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix^® platform harvests CTCs from blood and enables comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows - supporting research, drug development and clinical oncology.

Commercial activities centre on (i) biopharma clinical services, (ii) partnerships, (iii) development of laboratory-developed tests (LDTs), and (iv) Research Use Only validation of existing commercial proteomic and genomic assays. The product portfolio comprises the Parsortix^® platform with associated consumables and assays. Biopharma services are delivered from ANGLE's GCLP-compliant UK laboratory, providing bespoke LDT development, clinical-trial testing and custom services.

For more information, visit www.angleplc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc

View the original press release on ACCESS Newswire

FAQ

Who is the interim CEO of ANGLE plc (ANPCY) and when was he appointed?

Peter Collins was appointed interim CEO on 16 October 2025.

What experience does Peter Collins bring to ANGLE plc (ANPCY)?

He brings >25 years in oncology diagnostics and drug development, including roles at SAGA Diagnostics, Inivata, Guardant Health and GSK.

Who is Klaas de Boer and what will he do for ANGLE plc (ANPCY)?

Klaas de Boer joins as a senior board advisor, bringing >25 years in venture and finance to support the planned Q4 restructure and funding.

Will ANGLE plc (ANPCY) change its company name and to what?

Yes; ANGLE plc will be renamed CelLBxHealth plc as disclosed in the announcement.

Does Peter Collins join the ANGLE plc (ANPCY) board?

No; the announcement states he joins in a non‑board capacity as interim CEO.

What near-term corporate actions did ANGLE plc (ANPCY) announce for Q4 2025?

The company announced a restructure and funding process planned for Q4 2025.